HSP90 expression and its association with wighteone metabolite response in HER2‑positive breast cancer cells

Cao,Zhong‑Wei; Zeng,Qian; Pei,Hai‑Jiang; Ren,Li‑Dong; Bai,Hai‑Zhen; Na,Ri‑Na

doi:10.3892/ol.2016.4488

HSP90 expression and its association with wighteone metabolite response in HER2‑positive breast cancer cells

Authors:
- Zhong‑Wei Cao
- Qian Zeng
- Hai‑Jiang Pei
- Li‑Dong Ren
- Hai‑Zhen Bai
- Ri‑Na Na
View Affiliations

Affiliations: Department of Thyroid, Breast, Hernia and Vascular Surgery, The Inner Mongolia Autonomous Region People's Hospital, Hohhot, Inner Mongolia Autonomous Region 010017, P.R. China, Department of Neurology, The Inner Mongolia Autonomous Region People's Hospital, Hohhot, Inner Mongolia Autonomous Region 010017, P.R. China
Published online on: April 21, 2016 https://doi.org/10.3892/ol.2016.4488
Pages: 3719-3722

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

It is well known that heat shock protein 90 (HSP90) overexpression is correlated with poor prognosis and chemo‑resistance in human malignant cancers. At the same time, wighteone, or 6‑prenyl‑5,7,4'‑trihydroxyisoflavone, a major isoflavone component of the ornamental tall tree Erythrina suberosa, has been demonstrated to exhibit a potent anti‑proliferative effect on human leukemia HL‑60 cancer cell lines. In this study, the effects of wighteone on the proliferation of HER2‑positive breast cancer cells were investigated, and the action mechanism was explored. MCF‑7 HER2‑positive breast cancer cells were treated with various concentrations of wighteone. The growth inhibitory rate of the cells was calculated by MTT assay, apoptosis was detected by flow cytometry, and the expression level of HSP90 was assessed by western blot analysis. The addition of wighteone at concentrations ranging from 1‑10 g/ml in the medium for 48 h had a marked inhibition on the proliferation of HER2‑positive cancer cell lines. The growth inhibitory rates with 0.5, 2 or 8 mM wighteone were significantly higher compared with the control group. Apoptosis in the wighteone‑treated cells was also significantly higher compared with the control group. The expression level of HSP90 in the wighteone group was significantly lower than that in the control group. Our findings demonstrated that wighteone effectively inhibited the proliferation of HER2‑positive cancer cell lines, and this is considered to be the result of downregulating HSP90 receptor and downstream signaling.

View Figures

View References

1	American Cancer Society: Cancer Facts & Figures 1994. American Cancer Society. Atlanta, GA: 131994.
2	Kumar S, Pathania AS, Saxena AK, et al: The anticancer potential of flavonoids isolated from the stem bark of Erythrina suberosa through induction of apoptosis and inhibition of STAT signaling pathway in human leukemia HL-60 cells. Chem Biol Interact. 205:128–137. 2013. View Article : Google Scholar : PubMed/NCBI
3	Hanahan D and Weinberg RA: The hallmarks of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
4	Baselga J and Swain SM: Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 9:463–475. 2009. View Article : Google Scholar : PubMed/NCBI
5	Beliakoff J and Whitesell L: Hsp90: an emerging target for breast cancer therapy. Anticancer Drugs. 15:651–662. 2004. View Article : Google Scholar : PubMed/NCBI
6	Mendelsohn J and Baselga J: Epidermal growth factor receptor targeting in cancer. Semin Oncol. 33:369–385. 2006. View Article : Google Scholar : PubMed/NCBI
7	Solit DB and Chiosis G: Development and application of Hsp90 inhibitors. Drug Discov Today. 13:38–43. 2008. View Article : Google Scholar : PubMed/NCBI
8	Mendelsohn J and Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 21:2787–2799. 2003. View Article : Google Scholar : PubMed/NCBI
9	Citri A, Kochupurakkal BS and Yarden Y: The Achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle. 3:51–60. 2004. View Article : Google Scholar : PubMed/NCBI
10	Taldone T, Sun W and Chiosis G: Discovery and development of heat shock protein 90 inhibitors. Bioorg Med Chem. 17:2225–2235. 2009. View Article : Google Scholar : PubMed/NCBI
11	Whitesell L and Lindquist SL: HSP90 and the chaperoning of cancer. Nat Rev Cancer. 5:761–772. 2005. View Article : Google Scholar : PubMed/NCBI
12	Pick E, Kluger Y, Giltnane JM, et al: High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res. 67:2932–2937. 2007. View Article : Google Scholar : PubMed/NCBI
13	Song CH, Park SY, Eom KY, et al: Potential prognostic value of heat-shock protein 90 in the presence of phosphatidylinositol-3-kinase overexpression or loss of PTEN, in invasive breast cancers. Breast Cancer Res. 12:R202010. View Article : Google Scholar : PubMed/NCBI
14	Smith-Jones PM, Solit D, Afroze F, Rosen N and Larson SM: Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J Nucl Med. 47:793–796. 2006.PubMed/NCBI
15	Costantini DL, Bateman K, McLarty K, et al: Trastuzumab-resistant breast cancer cells remain sensitive to the Auger electron-emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate. J Nucl Med. 49:1498–1505. 2008. View Article : Google Scholar : PubMed/NCBI
16	Orlova A, Wållberg H, Stone-Elander S and Tolmachev V: On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in murine xenograft model. J Nucl Med. 50:417–425. 2009. View Article : Google Scholar : PubMed/NCBI
17	Kramer-Marek G, Kiesewetter DO and Capala J: Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-labeled affibody molecules. J Nucl Med. 50:1131–1139. 2009. View Article : Google Scholar : PubMed/NCBI
18	Dijkers EC, Kosterink JG, Rademaker AP, et al: Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med. 50:974–981. 2009. View Article : Google Scholar : PubMed/NCBI
19	Newman DJ and Cragg GM: Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod. 75:311–335. 2012. View Article : Google Scholar : PubMed/NCBI
20	Hargreaves RT, Jonson RD, Millington DS, et al: Alkaloids of American species of Erythrina. Lloydia. 37:569–580. 1974.PubMed/NCBI
21	Chopra RN, Nayar SL and Chopra IC: Glossary of Indian Medicinal Plants. CSIR. New Delhi: 1956.
22	Garín-Aguilar ME, Luna JE, Soto-Hernández M, et al: Effect of crude extracts of Erythrina americana Mill. on aggressive behavior in rats. J Ethnopharmacol. 69:189–196. 2000. View Article : Google Scholar : PubMed/NCBI
23	Agrawal SK, Agrawal M, Sharma PR, et al: Induction of apoptosis in human promyelocytic leukemia HL60 cells by an extract from Erythrina suberosa stem bark. Nutr Cancer. 63:802–813. 2011. View Article : Google Scholar : PubMed/NCBI
24	Gallegos Ruiz MI, Floor K, Roepman P, Rodriguez JA, et al: Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. PLoS One. 3:e00017222008.PubMed/NCBI
25	Garcia-Carbonero R, Carnero A and Paz-Ares L: Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol. 14:e358–e369. 2013. View Article : Google Scholar : PubMed/NCBI
26	Pick E, Kluger Y, Giltnane JM, Moeder C, Camp RL, Rimm DL and Kluger HM: High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res. 67:2932–2937. 2007. View Article : Google Scholar : PubMed/NCBI
27	Ciocca DR, Clark GM, Tandon AK, Fuqua SA, Welch WJ and McGuire WL: Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications. J Natl Cancer Inst. 85:570–574. 1993. View Article : Google Scholar : PubMed/NCBI
28	Kim LS and Kim JH: Heat shock protein as molecular target for breast cancer therapeutics. J Breast Cancer. 14:167–174. 2011. View Article : Google Scholar : PubMed/NCBI